((Gasp))
<<Wheeze>>
 

.... I'm sure I've got asthma

A FeNO test is the yes or no decider

Asthma is a chronic respiratory condition which affects around 300 million people globally. It is usually characterised by airway inflammation and is defined by the history of several symptoms, such as wheeze, cough, shortness of breath, and chest tightness, all of which can vary over time and intensity.

---

FeNO testing measures the level of inflammation (fractional exhaled nitric oxide) in the airways though a simple, one-result breath test helping to diagnose and manage asthma.

 

---

The NIOX FeNO Device



Benefits of the NIOX FeNO test

 

• Very quick test to perform with results in less than 2 minutes
• Accurate reading giving immediate diagnosis or update on management of the condition
• The result makes for easier treatment in selecting ICS medications and dosage (inhalers)

 

How the test is performed:

 

1. With NIOX VERO®, taking a test is as simple as breathing, patients simply inhale and exhale through the device
2. The device then displays the FeNO level on screen which can be easily interpreted by the clinician on hand

 

Guide to result interpretation: https://www.niox.com/en-gb/feno-asthma/interpreting-feno/ 

 

---

 

How the NIOX FeNO test makes for potential savings:

Time saving

 

• A baseline, no-nonsense test determining if patient has asthma or an update on condition
• Quick 2 minute test with immediate result
• Easy single result interpretation and subsequent treatment
• No specialist training for clinicians required to use the device
• The only consumable to change between tests is the mouthpiece, and all surfaces are easily wipeable

 

 

Cost saving:

 

• Select a testing bundle which works for you

The NIOX FeNO consumable aspect is sold as a test kit - a sensor with either 100, 300, 500 or 1000 tests, and the equivalent number of mouthpieces 
Test sensors expire after all tests have been used or 1 year since installation, whichever comes first. 
Cost per test ranges between £4.00 to £11.00, by using every test on your device, you’ll get better value for money


 

Savings in prescribing

 

• With accurate diagnosis, no patient will needlessly be prescribed an inhaler if they do not suffer from asthma

Better management, as poor asthma control accounts for such a large percentage of asthma costs. 
FeNO is exquisitely sensitive to ICS medications. This means that if a patient presents with a high FeNO, it is likely that ICS medications would lower their FeNO levels. This can help to improve patient outcomes and control of their condition.
Due to being sensitive to ICS, FeNO can also help you to monitor adherence or notice if patients do not have correct inhaler technique.

A report by Asthma and Lung UK, estimated that FeNO testing could lead to savings of £147 million, and by improving patent adherence it has been predicted that this could lead to savings of £292 million in the UK.


 

Pressure off the hospitals

In the UK, asthma leads to around 60,000 hospital admissions per year and costs £6 billion, which includes productivity and quality of life costs. Poor asthma control is linked to higher expenses, accounting for up to 75% of all asthma-related costs.


 

---

In summary, incorporating NIOX FeNO testing into asthma care pathways offers significant clinical and economic advantages. From quick, accurate diagnoses to improved management and reduced healthcare costs, this tool supports better outcomes for both patients and healthcare systems.




 

---

References:
https://www.niox.com/en-gb/digital-platform/feno-reduce-ics-dosage
https://www.niox.com/en-gb/digital-platform/feno-cost-effective 
https://www.niox.com/en-gb/videos/educational-videos/performing-test/